Overall Survival Benefit Up for Pyrotinib + Capecitabine in HER2-Positive Breast Cancer
THURSDAY, Nov. 16, 2023 -- For patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, pyrotinib plus capecitabine offers an overall survival benefit, according to a study presented at the Advanced Breast... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 16, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Basel, 19 October 2023Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecen...
Source: Roche Media News - October 19, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecentriqPositive phase III...
Source: Roche Investor Update - October 19, 2023 Category: Pharmaceuticals Source Type: news
Shorter Capecitabine Dosing in Metastatic Breast Cancer Shorter Capecitabine Dosing in Metastatic Breast Cancer
A fixed dose of capecitabine given on a 7-day-on, 7-day-off schedule had similar efficacy and reduced adverse events compared with the standard 14-day-on, 7-day-off schedule.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 16, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
' New Standard of Care' for Capecitabine Hand-Foot Syndrome'New Standard of Care' for Capecitabine Hand-Foot Syndrome
Topical gel with 1% diclofenac should be the new standard of care to prevent this side effect, say oncologists highlighting what they describe as the best study from the recent ASCO meeting.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 15, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Mark Cuban's Pharmacy Adds Another Onc Drug: Capecitabine Mark Cuban's Pharmacy Adds Another Onc Drug: Capecitabine
But will current drug shortages limit the supply of this generic cancer drug and others sold by Cuban ' s Cost Plus Drug Company?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 26, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Roche to present new data in blood cancers and solid tumours from its broad portfolio at ASCO 2023
Basel, 26 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer types at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held 2 – 6 June. Highlights include new data spanning treatments for lymphoma and hepatocellular carcinoma (HCC):Developing new treatment options for people with blood cancersExtended follow-up data for Columvi ® (glofitamab) of almost two years (20 months) from the pivotal phase II NP30179 study, further investigating the potential of fixed-duration Columvi to provide durable responses in people...
Source: Roche Investor Update - May 26, 2023 Category: Pharmaceuticals Source Type: news
Another Win for Zolbetuximab in Advanced Gastric/GEJ Cancer
(MedPage Today) -- Zolbetuximab plus capecitabine and oxaliplatin (CAPOX) improved survival outcomes in patients with Claudin (CLDN)18.2-positive, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinomas... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - March 24, 2023 Category: Gastroenterology Source Type: news
Capecitabine's Label Updated Under FDA Project Renewal Initiative Capecitabine's Label Updated Under FDA Project Renewal Initiative
Project Renewal is updating the labels of older oncology drugs to reflect current evidence.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 16, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Survival Benefit With Capecitabine Maintenance in Metastatic CRC Survival Benefit With Capecitabine Maintenance in Metastatic CRC
A new analysis reveals a significant reduction in the risk of death with capecitabine maintenance vs active monitoring. The study was published as a preprint and has not yet been peer reviewed.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - December 7, 2022 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news
Adjuvant Capecitabine for Early Breast Cancer Adjuvant Capecitabine for Early Breast Cancer
Could adjuvant treatment with capecitabine provide survival benefits in early breast cancer? A long-term follow-up of these patients provides insight.Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 22, 2022 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncol...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news
Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data on glofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Onc...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news
Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Onco...
Source: Roche Investor Update - May 24, 2022 Category: Pharmaceuticals Source Type: news
Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncol...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news
